In addition, several avenues warrant further in-depth investigation, such as whether and how meningeal immune mechanisms contribute to the therapeutic effects of VEGF-C in AD; the long-term effects of mLV ablation if ablating meningeal lymphatics can reduce excessive inflammatory responses in MS; and whether early regulation of meningeal immunity could potentially slow disease progression. The gene discussed is VEGFC; the disease is myeloid sarcoma.